Ventyx Biosciences
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
| Company Details | |
|---|---|
| Title | Ventyx Biosciences |
| Industries | Biopharma, Biotechnology |
| Headquarters Regions | Greater San Diego Area, West Coast, Western US |
| Headquarters Location | Encinitas, California, United States |
| No Of Employees | 11-50 |
| Operating Status | Active |
Description
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.